Cargando…

Targeting CXCR4 in AML and ALL

The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) blasts with the bone marrow microenvironment regulates self-renewal, growth signaling, as well as chemotherapy resistance. The chemokine receptor, CXC receptor 4 (CXCR4), with its ligand chemokine ligand 12 (CXCL1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cancilla, Daniel, Rettig, Michael P., DiPersio, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499473/ https://www.ncbi.nlm.nih.gov/pubmed/33014834 http://dx.doi.org/10.3389/fonc.2020.01672

Ejemplares similares

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide
por: Crees, Zachary D., et al.
Publicado: (2023)

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

Mobilized peripheral blood: an updated perspective
por: Karpova, Darja, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
por: Crees, Zachary D., et al.
Publicado: (2023)

Suicide genes: monitoring cells in patients with a safety switch
por: Eissenberg, Linda G., et al.
Publicado: (2014)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML
por: Jia, Yannan, et al.
Publicado: (2023)

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
por: Zaitseva, Lyubov, et al.
Publicado: (2014)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

Calcineurin/CXCR4 in T-ALL
por: Passaro, Diana, et al.
Publicado: (2015)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells
por: Wilson, Elisabeth R., et al.
Publicado: (2021)

CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment
por: Santagata, Sara, et al.
Publicado: (2021)

Mouse models of graft-versus-host disease: advances and limitations
por: Schroeder, Mark A., et al.
Publicado: (2011)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
por: Nehrbas, Jill, et al.
Publicado: (2020)

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment
por: Longmate, Whitney, et al.
Publicado: (2017)

Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway
por: Yue, Dongli, et al.
Publicado: (2020)

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

The Graft-Versus-Leukemia Effect in AML
por: Sweeney, Connor, et al.
Publicado: (2019)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Editorial: The latest advances in transplantation for AML
por: Chiusolo, Patrizia, et al.
Publicado: (2023)

The Role of CXCR1, CXCR2, CXCR3, CXCR5, and CXCR6 Ligands in Molecular Cancer Processes and Clinical Aspects of Acute Myeloid Leukemia (AML)
por: Korbecki, Jan, et al.
Publicado: (2023)

FEV Maintains Homing and Expansion by Activating ITGA4 Transcription in Primary and Relapsed AML
por: Zhang, Jubin, et al.
Publicado: (2022)

Corrigendum: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway
por: Yue, Dongli, et al.
Publicado: (2022)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
por: Lang, Jonas B., et al.
Publicado: (2022)

CXCR4 Mediates Enhanced Cell Migration in CALM-AF10 Leukemia
por: Fertal, Shelby A., et al.
Publicado: (2022)

The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate
por: Klement, Laura, et al.
Publicado: (2023)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation
por: Alahmari, Bader, et al.
Publicado: (2018)

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 (low) Mice
por: Verachi, Paola, et al.
Publicado: (2022)

Integrin Regulation of CAF Differentiation and Function
por: DiPersio, C. Michael, et al.
Publicado: (2019)

Towards a Better Understanding of Cohesin Mutations in AML
por: Cuartero, Sergi, et al.
Publicado: (2019)

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML
por: Stockard, Bradley, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a2qt6r5cta0o95pbdj9b92ob9c